CD9 and ovarian cancer: The results presented are consistent with our earlier data on the preferential expression of MMP9 on the surface of CD9-positive sEVs compared with MMP2 and TIMP1 in healthy women, patients with borderline ovarian tumors, and patients with ovarian cancer, and MMP9-positive exosomes were more frequently found in CRCPs [21].